|Bid||136.20 x 100|
|Ask||138.63 x 100|
|Day's Range||133.25 - 138.75|
|52 Week Range||96.18 - 145.42|
|PE Ratio (TTM)||65.84|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16.
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.